PARADISE-MI
A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to Ramipril in acute MI patients with evidence of LV dysfunction (but without prior history of chronic HF)
- Stage
- klaar
- Medicine
- LCZ696
- Population
- ASCVD
- Phase
- III
- First Patient In
- 9 February 2017
- Last Patient In
- 17 April 2020
- Last Patient Last Visit
- 16 February 2021
National Lead
dr. P van der Meer
Cardioloog
Study Director
